Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- NRIX
- Price
- 19.39
- Stock movement up
- +0.37 (1.95%)
- Company name
- Nurix Therapeutics Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 1.97B
- Ent value
- 2.04B
- Price/Sales
- 23.49
- Price/Book
- 5.28
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- 16.44%
- 1 year return (CAGR)
- -1.07%
- 3 year return (CAGR)
- -
- 5 year return (CAGR)
- -
- 10 year return (CAGR)
- -
Last updated: 2026-01-22
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
NRIX does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 23.49 |
| Price to Book | 5.28 |
| EV to Sales | 24.34 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 101.37M |
| EPS (TTM) | -2.91 |
| FCF per share (TTM) | -2.87 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 83.69M |
| Gross profit (TTM) | -136.30M |
| Operating income (TTM) | -267.23M |
| Net income (TTM) | -244.78M |
| EPS (TTM) | -2.91 |
| EPS (1y forward) | -3.41 |
Margins
Loading...
Margins data
| Gross margin (TTM) | -162.86% |
| Operating margin (TTM) | -319.32% |
| Profit margin (TTM) | -292.50% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 78.44M |
| Net receivables | 1.70M |
| Total current assets | 440.60M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 114.26M |
| Total assets | 522.47M |
| Accounts payable | 8.61M |
| Short/Current long term debt | 56.49M |
| Total current liabilities | 82.35M |
| Total liabilities | 150.22M |
| Shareholder's equity | 372.25M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -230.38M |
| Capital expenditures (TTM) | 10.98M |
| Free cash flow (TTM) | -241.36M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -65.76% |
| Return on Assets | -46.85% |
| Return on Invested Capital | -65.09% |
| Cash Return on Invested Capital | -64.18% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 19.00 |
| Daily high | 20.18 |
| Daily low | 19.00 |
| Daily Volume | 1.43M |
| All-time high | 50.17 |
| 1y analyst estimate | 28.41 |
| Beta | 1.88 |
| EPS (TTM) | -2.91 |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | 18 Feb 2026 |
Downside potential
Loading...
Downside potential data
| NRIX | S&P500 | |
| Current price drop from All-time high | -61.35% | -0.89% |
| Highest price drop | -83.58% | -19.00% |
| Date of highest drop | 23 Sep 2025 | 8 Apr 2025 |
| Avg drop from high | -69.92% | -2.49% |
| Avg time to new high | - | 6 days |
| Max time to new high | 322 days | 89 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
1.97B
Marketcap category
Small-cap
Description
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader, that is in Phase 1A clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, that is in Phase 1A clinical trials to treat immuno-oncology indications. It is also developing NX 0479/GS 6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc. (Gilead), Sanofi S.A. (Sanofi), and Pfizer Inc. (Pfizer) for co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.
Employees
286
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page